173 related articles for article (PubMed ID: 14682120)
21. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib (Tarceva) for advanced non-small cell lung cancer.
Med Lett Drugs Ther; 2005 Mar; 47(1205):25-6. PubMed ID: 15795683
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
24. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
26. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
28. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
31. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
32. Screening for epidermal growth factor receptor mutations in lung cancer.
Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
[TBL] [Abstract][Full Text] [Related]
33. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
34. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
38. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
[TBL] [Abstract][Full Text] [Related]
39. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
[TBL] [Abstract][Full Text] [Related]
40. Erlotinib: preclinical investigations.
Hidalgo M
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):11-6. PubMed ID: 14682118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
